.svg){kind=small}
Jul-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Where to Buy
Fairwinds is stocked at 201 licensed dispensaries across Washington, with the deepest coverage in Seattle, Tacoma, Spokane, Bellevue, and Bellingham. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
In July 2026, Fairwinds concentrated 57.92% of sales in Tincture & Sublingual, where year-over-year sales declined 15.26% but month-over-month rose 25.79%, while Vapor Pens held 19.27% share with a 3.24% YoY increase and a 14.28% MoM lift. Capsules’ 11.22% share contracted with a 33.24% YoY drop and a 5.64% MoM decline, and Topical at 10.22% share fell 27.53% YoY but improved 7.63% MoM. Long-tail categories compressed further: Concentrates were down 59.42% YoY with a 1.00% MoM uptick, and Flower shrank 87.41% YoY despite a 25.07% MoM rise, while Pre-Roll decreased 63.45% YoY and 39.24% MoM. The pattern implies short-term momentum is consolidating in the two largest franchises—Tincture & Sublingual and Vapor Pens—while therapeutic formats like Capsules and Topical are ceding mix, indicating a tilt toward fewer, faster-moving categories in Washington.
Holding the number 1 rank in Tincture & Sublingual in Washington alongside a 25.79% MoM jump suggests Fairwinds can defend category leadership even as brand-level sales fell 18.92% YoY and average price declined 2.25% YoY. The 3.24% YoY growth and 14.28% MoM lift in Vapor Pens, combined with Capsules’ 33.24% YoY contraction and Topical’s 27.53% YoY decline, points to a positioning anchored in functional ingestibles plus inhalable adjacency rather than a broad portfolio; the near-negligible 0.03% share in Pre-Roll and 0.34% in Flower reinforces deliberate de-prioritization. The implication is that brand equity is concentrated where it ranks first, with price elasticity managed via a sub-3% YoY price reduction, and share gains are more attainable by deepening penetration in Tincture & Sublingual and leveraging cross-over into Vapor Pens than by reviving low-share categories.
Competitive Landscape
Fairwinds sits at rank #1 in Washington Tincture & Sublingual in July 2026, unchanged YoY at #1, after climbing from #2 in April 2026 to its peak at #1 in July 2026; meanwhile, Green Revolution held at #2 YoY while its sales fell 1.9%, and HiKu advanced from #4 YoY to #3 with a 53.8% sales increase. Against that backdrop, Ceres slipped from #3 YoY to #4 alongside a 29.5% sales decline, while Canna Cantina remained at #5 YoY with a 9.7% drop; this pattern implies Fairwinds’ return to #1 and stability at the top hinge on defending share against faster-rising mid-pack challengers rather than legacy #2 incumbents.
Notable Products
CBD/THC 5:1 Companion Savory Bacon 64x Tincture (200mg CBD, 40mg THC, 8ml, 0.54 fl oz) posted the largest month-over-month surge at 52.2% and rose to rank 1, while the CBD/THC 5:1 Companion Roasted Chicken 32x Tincture climbed 50.8% to rank 4, indicating flavor-led extensions are converting into higher shelf positions. The CBD/THC 5:1 Companion Savory Bacon 32x Tincture advanced 45.8% to rank 2, and with four of the top five in Tincture & Sublingual, the category concentration points to a deliberate tilt toward ratio-driven ingestibles; meanwhile, Capsules slipped as the CBD/CBG/THC FECO High Potency 20-Pack fell 15.0% to rank 6. The CBD/THC/CBG 1:1:1 Flow Cream Deep Tissue Relief increased 26.9% at rank 7 as the lone Topical in the top 10, but the new CBD/THC 20:1 Ratio Co2 Cartridge entered at rank 8 without a reported growth rate, balancing the portfolio with a single Vapor Pens SKU and $50,301 from the leading tincture anchoring revenue. Overall, Fairwinds is consolidating around high-ratio tinctures while testing adjacent form factors, implying a strategy to deepen share where velocity is rising and to prune underperforming capsule formats.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
